SCHEDULE: Damon DeSantis Discloses 41.3% Stake in Integrated Biopharma

Damon DeSantis and CDDS 2.0, LLC have reported a combined 41.3% beneficial ownership stake in Integrated Biopharma, Inc. following a series of internal share transfers.

Summary

• Damon DeSantis and his entity, CDDS 2.0, LLC, have filed a Schedule 13D reporting a combined beneficial ownership of 12,920,558 shares of Integrated Biopharma, Inc. common stock.
• This ownership represents approximately 41.3% of the company's 31,059,610 outstanding shares as of April 15, 2026.
• The shares were acquired through a series of transfers from CD Financial, LLC, the Carl DeSantis Revocable Trust, and the Estate of Carl DeSantis for no cash consideration.
• Damon DeSantis holds 187,500 shares directly via exercisable stock options and controls the 12,733,058 shares held by CDDS 2.0, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine disclosure of internal asset transfers and ownership consolidation rather than a change in the company's operational or financial performance.

Positives

• Consolidation of significant shareholding under a single controlling individual, Damon DeSantis, which may provide stability in corporate governance.
• The acquisition of shares involved no cash consideration, indicating an internal restructuring of family or estate assets rather than a market-based purchase.

Negatives

• High concentration of ownership (41.3%) by a single group may limit the influence of minority shareholders.
• The filing notes that the reporting persons reserve the right to change their intentions, which could lead to future volatility or strategic shifts.

Risks

• Concentration of voting power allows the reporting group to significantly influence or control corporate actions.
• Potential for future changes in investment intent, which could include plans for mergers, acquisitions, or changes to the board of directors.

Future Outlook

The reporting persons currently have no specific plans or proposals regarding the company, but reserve the right to change their intentions regarding future actions, including potential changes to the board or corporate structure.

Management Comments

• The reporting persons state they have no present intention or plans which relate to or could result in any of the matters referred to in paragraphs (a) through (j) of Item 4 of Schedule 13D.

Industry Context

StockSavvy.ai notes that this filing represents a significant consolidation of ownership within a small-cap biopharma entity, which is common in family-controlled firms but warrants monitoring for potential shifts in strategic direction or privatization efforts.

Comparison to Industry Standards

• The 41.3% ownership stake is high compared to typical institutional holdings in mid-to-large cap companies, but is consistent with family-controlled small-cap biotechnology firms.
• The lack of cash consideration for the transfer is standard for estate planning and internal asset reorganization.

Related Party Transactions

• The shares were transferred between related entities including CD Financial, LLC, the Carl DeSantis Revocable Trust, and the Estate of Carl DeSantis.

Stakeholder Impact

• Shareholders should be aware of the high concentration of voting power held by the DeSantis group.
• Employees and creditors may see this as a sign of continuity in ownership.

Next Steps

• Monitor for any future amendments to the Schedule 13D if the reporting group changes their investment intent.

Key Dates

Keywords

Integrated Biopharma, Schedule 13D, Damon DeSantis, Beneficial Ownership, Corporate Governance, Shareholder Disclosure